Key facts
- It has raised $332.4M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Fidelity International, VMS Group (Hong Kong), Biomark Capital, Panacea Capital (California).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Chime Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Chime Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chime Biologics
Developer and manufacturer of biological products designed to provide customers with a one-stop biopharmaceutical chemistry, manufacturing and controls (CMC) solution. The company offers omclude water injection, freeze drying and pre-filling medicine and supports early drug development to late clinical research and commercial cGMP production to meet the dynamic needs of the biopharmaceutical industry, thereby providing patients with affordable medicine options and improved level of treatment.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2013
- Employees
- 600
- Website
- chimebiologics.com/
- Ownership
- Privately Held (backing)
Chime Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chime Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chime Biologics in its N-PORT filings yet. We sweep new filings monthly.